v3.26.3
Statements of Consolidated Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2024
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS      
Net income (loss) $ 4,000,000 $ (845,000,000) $ 169,000,000
Loss from discontinued operations, net of income taxes 21,000,000 23,000,000 30,000,000
Adjustments to reconcile income (loss) from continuing operations to cash flows from operating activities      
Depreciation and amortization 185,000,000 237,000,000 274,000,000
Original issue discount and debt issuance cost amortization 8,000,000 7,000,000 6,000,000
Deferred income taxes 7,000,000 73,000,000 (302,000,000)
Gain from sales of property and equipment (5,000,000) (16,000,000) 0
Equity income from affiliates (1,000,000) 0 0
Stock based compensation expense - Note O 18,000,000 14,000,000 15,000,000
Loss from excess tax deduction on stock based compensation (1,000,000) (3,000,000) 0
Income from restricted investments (21,000,000) (33,000,000) (74,000,000)
Loss on divestitures, net - Note B 13,000,000 177,000,000 107,000,000
Goodwill impairment 0 706,000,000 0
Asset impairments 18,000,000 0 11,000,000
Pension contributions (12,000,000) (12,000,000) (15,000,000)
(Gain) loss on pension and other postretirement plan remeasurements (7,000,000) (3,000,000) 14,000,000
Change in operating assets and liabilities [1] 158,000,000 (191,000,000) 227,000,000
Total cash flows provided by operating activities from continuing operations 385,000,000 134,000,000 462,000,000
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS      
Additions to property, plant and equipment (88,000,000) (98,000,000) (137,000,000)
Proceeds from disposal of property, plant and equipment 6,000,000 16,000,000 0
Proceeds from sale or restructuring of operations 2,000,000 16,000,000 26,000,000
Proceeds from settlement of company-owned life insurance contracts 27,000,000 12,000,000 1,000,000
Company-owned life insurance payments (4,000,000) (5,000,000) (5,000,000)
Funds restricted for specific transactions (9,000,000) (8,000,000) (5,000,000)
Reimbursement from restricted investments 74,000,000 62,000,000 79,000,000
Proceeds from sale of securities 71,000,000 56,000,000 53,000,000
Purchase of securities (71,000,000) (54,000,000) (53,000,000)
Other investing cash flows 0 0 (10,000,000)
Total cash flows provided (used) by investing activities from continuing operations 8,000,000 (3,000,000) (51,000,000)
CASH FLOWS USED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS      
Repayment of short-term debt 0 0 (16,000,000)
Repurchase of common stock 0 (100,000,000) (380,000,000)
Debt issuance costs (2,000,000) 0 0
Cash dividends paid (76,000,000) (76,000,000) (78,000,000)
Stock based compensation employee withholding taxes paid in cash (3,000,000) (3,000,000) (5,000,000)
Total cash flows used by financing activities from continuing operations (81,000,000) (179,000,000) (479,000,000)
CASH PROVIDED (USED) BY CONTINUING OPERATIONS 312,000,000 (48,000,000) (68,000,000)
Cash used by discontinued operations      
Operating cash flows (46,000,000) (40,000,000) (51,000,000)
Total cash used by discontinued operations (46,000,000) (40,000,000) (51,000,000)
Effect of currency exchange rate changes on cash and cash equivalents (1,000,000) 3,000,000 2,000,000
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 265,000,000 (85,000,000) (117,000,000)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR 215,000,000 300,000,000 417,000,000
CASH AND CASH EQUIVALENTS - END OF YEAR 480,000,000 215,000,000 300,000,000
CHANGES IN ASSETS AND LIABILITIES      
Accounts receivable, net (25,000,000) (3,000,000) 96,000,000
Inventories 87,000,000 (28,000,000) 79,000,000
Trade and other payables 26,000,000 (63,000,000) 56,000,000
Other assets and liabilities 70,000,000 (97,000,000) (4,000,000)
CHANGE IN OPERATING ASSETS AND LIABILITIES [1] 158,000,000 (191,000,000) 227,000,000
SUPPLEMENTAL DISCLOSURES      
Interest paid 53,000,000 54,000,000 52,000,000
Income taxes (received) paid, net (including discontinued operations) [2] $ (58,000,000) $ 33,000,000 $ 53,000,000
[1] Excludes changes resulting from operations sold.
[2] 2026 includes receipt of a tax refund related to the capital loss carryback from the Nutraceutical business sale of $103 million.